13:07:29 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOBX
SektorHälsovård
IndustriBioteknik
BerGenBio är ett norskt onkologibolag. Idag bedriver bolaget forskning och utveckling av hämmande läkemedel för behandling av aggressiva cancertyper. Bolaget har utvecklat ett flertal produkter vars sammansättning ämnar blockera proteinet AXL, ett protein positivt relaterat med spridning av cancercellerna. Bolaget grundades under 2007 och har sitt huvudkontor i Bergen.

Kalender

2021-11-16 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-19 Kvartalsrapport 2021-Q1
2021-03-22 Ordinarie utdelning BGBIO 0.00 NOK
2021-03-19 Årsstämma 2021
2021-02-10 Bokslutskommuniké 2020
2020-12-09 Extra Bolagsstämma 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-19 Kvartalsrapport 2020-Q1
2020-03-17 Ordinarie utdelning BGBIO 0.00 NOK
2020-03-16 Årsstämma 2020
2020-02-11 Bokslutskommuniké 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-19 Kvartalsrapport 2019-Q2
2019-05-08 Kvartalsrapport 2019-Q1
2019-03-14 Ordinarie utdelning BGBIO 0.00 NOK
2019-03-13 Årsstämma 2019
2019-02-19 Bokslutskommuniké 2018
2018-11-13 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-05-15 Kvartalsrapport 2018-Q1
2018-05-15 Ordinarie utdelning BGBIO 0.00 NOK
2018-05-14 Årsstämma 2018
2018-03-09 Extra Bolagsstämma 2018
2018-02-13 Bokslutskommuniké 2017
2017-11-17 Kvartalsrapport 2017-Q3
2017-08-18 Kvartalsrapport 2017-Q2
2017-05-23 Kvartalsrapport 2017-Q1
2017-03-23 Ordinarie utdelning BGBIO 0.00 NOK
2017-03-22 Årsstämma 2017
2016-06-22 Ordinarie utdelning BGBIO 0.00 NOK
2016-06-21 Årsstämma 2016
2015-06-23 Ordinarie utdelning BGBIO 0.00 NOK
2015-06-22 Årsstämma 2015
2020-04-14 07:00:14
Bergen, Norway, 14 April 2020 - The board of directors in BerGenBio ASA (the
"Company") (OSE:BGBIO) has granted options to employees.

The annual general meeting in the Company at 16 March 2020 approved the share
options program and authorised the board of directors of the Company to issue
share options to the Company's employees as part of a long-term incentive plan.

Options granted under the share option program vest over a three-year period and
each option, when exercised, will give the right to acquire one share in the
Company at exercise price. Options granted under the share option program expiry
eight years after grant date.

A total of 2,026,663 share options, equal to 2.76% of total shares issued in the
Company, were granted at an exercise price at NOK 15.00 constituting the average
traded price at OSE between 24 March and 7 April.

Of the total grant the following was granted to primary insiders (total holdings
of share options following this grant):



Richard Godfrey - CEO: 413,333 (1,542,617)

James B. Lorens - CSO: 178,533 (767,040)

Hani Gabra - CMO: 208,000 (208,000)

Rune Skeie - CFO: 146,667 (242,757)

James Barnes - Director of Operations: 178,000 (237,400)

Gro Gausdal - Director of research: 66,667 (158,376)

Alison Messom - Director of Clinical operations: 108,000 (108,000)

Endre Kjærland - Associate Director of IP and Contracts: 62,000 (150,525)



In total 1,361,200 share options were granted to primary insiders.

Following this grant a total of 4,552,060 share options are issued, equal to
6.21% of the total shares issued in the Company. Of this 1,679,611 share options
are vested and 2,872,449 not vested.

-End-

Contacts

Richard Godfrey

CEO, BerGenBio ASA

ir@bergenbio.com

+47 917 86 304

Rune Skeie

CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.